[English]  [Pусский]  [中文]  
ctt-journal > Baryakh et al. (Abstract)

Baryakh et al. (Abstract)

Cellular Therapy and Transplantation (CTT), Vol. 3, No. 12
doi: 10.3205/ctt-2011-No12-abstract08

© The Authors. This abstract is provided under the following license: Creative Commons Attribution 3.0 Unported

Abstract accepted for "5th Raisa Gorbacheva Memorial Meeting Hematopoietic Stem Cell Transplantation in Children and Adults", Saint Petersburg, Russia, September 18–20, 2011

Preliminary Program

Contribute a comment


Short-term high intensive protocol BL-M-04 for adult patients with Burkitt lymphoma: efficacy and toxicity

Elena A. Baryakh, Sergey K. Kravchenko, Eugene E. Zvonkov, Alexandra M. Kremenetskaya, Aminat U. Magomedova, Tatiana N. Obukhova

Hematological Scientific Center, Moscow, Russia

Correspondence: Elena A. Baryakh, Hematological Scientific Center, 4, Novy Zykovsky pr., Moscow, 125167, Russian Federation, E-mail: ebaryakh@spam is badgmail.com


Aim: To evaluate the efficacy and toxicity of the BL-M-04 protocol for adult patients with Burkitt lymphoma (BL).

Methods: Forty-six patients with BL were eligible for our study; 32 males and 14 females, mean age 29 years, participated between August 2003 and December 2010. The treatment was based on high intensive protocol BL-M-04. Stages I, II, III, and IV were diagnosed in 3, 5, 16, and 6 patients respectively. B-acute lymphoblastic leukemia (L3) was diagnosed in 16 (35%) patients. The main aim of the new treatment regimen was greater efficacy of therapy due to intensification and shorter treatment duration. The new protocol is based on the modified NHL-BFM protocol for high risk patients. As BL is a chemosensitive tumor that often regresses after 1–2 courses of chemotherapy, we decided to treat the BL patients with 4 courses of chemotherapy (2 induction and 2 consolidation courses). As BL is most sensitive to high dose methotrexate and cytarabine, we used these drugs in the induction phase to achieve to maximize the cytoreductive effect. Courses A and C were used to achieve remission. Doxorubicin was added to course A, and methotrexate to course C. Consolidation courses were similar to induction courses. Here, we used A and C courses (without course B), intensified with course B drugs (doxorubicin and methotrexate), the interval between the courses being 21 days.

Results: Forty-one patients (89%) achieved a complete remission. Thirty-nine are alive in the first CR over 50 months. Seven patients died: 4 patients due to chemotherapy-related complications, 1 from disease progression, and 2 from early relapse. The 5-year disease-free survival was 95% with an overall survival of 85%.

Conclusions: The use of this protocol can achieve rapid tumor regression with short treatment duration due to chemotherapy intensification and acceptable toxicity.

Keywords: Burkitt lymphoma, treatment, adult